News & Updates

For young children with an upper respiratory tract infection, also known as common cold, treatment with hypertonic saline nasal drops is safe and beneficial, shortening recovery time by 2 days and, in turn, reducing household spread of the disease, according to the results of the ELVIS-Kids trial.

The SCOFF* trial presented at ESC 2024 shows that fasting is not necessary prior to cardiac catheterization procedures requiring conscious sedation.

Treatment with dupilumab reduced airway mucus plug scores and volume in patients with uncontrolled, moderate-to-severe asthma, according to the phase IV VESTIGE trial presented at ERS 2024.

New drug applications approved by US FDA as of 16-31 August 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with evogliptin falls short of providing protective benefits against calcification of the aortic valve (AV), but longer treatment may be helpful, reports a study.

GMRx2, a novel low-dose single pill containing three antihypertensive drugs – telmisartan, amlodipine, and indapamide – achieves all efficacy endpoints in two pivotal phase III trials presented at ESC 2024.